In Section C, members will acquire ABBV-744 and oral navitoclax. In Section D, members will acquire ABBV-744 and ruxolitinib. Members will get treatment until finally disease progression or even the members are not able to tolerate the study drugs. Doable new approaches to the prognosis and treatment of AML. (A) https://abbv-744-in-the-treatment81345.blogrenanda.com/38059114/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets